The Research Grant Program stimulates epilepsy research by providing funding for investigators in the early stages of their careers. Seed grants are awarded to clinical investigators or basic scientists for support of biological or behavioral research which will advance the understanding, treatment, and prevention of epilepsy.
One- and two-year Research Grants fund clinical and laboratory investigators in the early stages of their careers. Established researchers (Associate Professor level or above) are ineligible for the grants, which seed studies in biology and behavior to advance understanding, treatment, and prevention of epilepsy.
Past awardees include:
A nanotechnology approach to developing new treatments for epilepsyKevin Murnane, Ph.D. Assistant Professor Mercer University Macon, GA, United States
Epilepsy is a family of chronic neurologic disorders characterized by periodic, unpredictable seizures. Following drug treatment for epilepsy, more than 30% of patients continue to experience seizures. A critical barrier in the epilepsy field is many drugs that could potentially be used to control seizures have properties that prevent them from entering the brain. In the proposed studies, we intend to focus on the development of a new technology to actively transport these compounds into the brain. We will focus our efforts on neuropeptide Y and oxytocin, as there is evidence that these compounds control seizure activity, we have generated exciting preliminary data supporting the use of our technology to transport these compounds into the brain, and these compounds are excellent prototypes with which to demonstrated the feasibility of our novel technology.
Understanding pediatric to adult epilepsy transition care gapsChristine Baca, M.D. Assistant Professor UCLA Los Angeles, CA, United States
Despite the observation that over half of children with epilepsy have seizures remit during childhood, with many able to discontinue anti-seizure medication (ASM), there remains a substantive proportion of children who continue to have active seizures, require ongoing treatment with ASMs or have significant epilepsy related comorbidity that requires ongoing specialty care with a neurologist or epileptologist. As such, as children with epilepsy develop into adolescents and young adults, there is a need to transition (a process of preparation) and then transfer care from a pediatric to an adult provider. Transitions of care from pediatrics to adults can often be complex for adolescents with chronic medical conditions. Delineating the extent to which transition care gaps exist for patients with epilepsy is imminently needed. This project will use a mixed methods approach to measure transition care in adolescents with epilepsy, evaluate predictors of such care, and then examine pediatric and adult epilepsy care provider perceptions of such barriers to and facilitators of effective epilepsy transition care and clinic models. These results will be used to inform the development of a future transition care model.
Neurotrophins and fetal anticonvulsant syndromeKevin Bath, Ph.D. Assistant Professor Brown University Providence, RI, United States
This proposal will use preclinical models of early life exposure to anti-seizure medications to test the hypothesis that multiple AEDs contribute to a common disruption in brain development underlying many of the observed AED side effects.
The role of miRNA-mediated regulation of Kv4.2 during status epilepticusChristina Gross, Ph.D. Assistant Professor Emory University Atlanta, GA, United States
A major challenge in epilepsy research is the identification of therapeutic strategies that are beneficial for patients with epilepsy disorders of different etiologies. Potassium channels play an important role to control neuronal activity and excitability in the brain, and might thus be promising therapeutic targets. This research will analyze how a specific potassium channel, Kv4.2, a major player to limit brain activity, is controlled by a group of small RNAs. In the future, these small RNAs might be used as therapeutic tools to manipulate Kv4.2 function and modulate brain activity in epilepsy of different etiologies.
Contribution of cortical interneurons to epilepsyIllya Kruglikov, Ph.D. Research Assistant Professor New York University, School of Medicine New York, NY, United States
Healthy brain function depends on a precise balance of excitation and inhibition. Decreasing inhibition causes runaway excitation and consequently epilepsy. Inhibition is provided by a small and diverse group of neurons called interneurons. This project addresses the contribution of different cortical interneuron types to the development of epilepsy by genetically removing a protein, which when mutated known to cause epilepsy in humans. One goal of this project is to study the type of epileptic seizures produced by affecting specific interneuron populations. Another is to understand the wiring of cortical circuits leading to seizure generation. This project will advance our understanding of the cellular and circuit mechanisms of epilepsy.
Interaction between TrkB signaling in interneurons and epilepsyKeri Martinowich, Ph.D. Investigator Lieber Institute Baltimore, MD, United States
Epilepsy is a disorder characterized by recurrent seizures that arise from disruptions in neuron firing patterns that lead to excessive excitation. Understanding the cellular and molecular mechanisms that lead to hyperexcitability and spontaneous seizures is crucial to identify targets for drug development. Investigations of the cellular and molecular origins of brain hyperexcitability leading to epilepsy have identified the brain-derived neurotrophic factor (BDNF). There is extensive evidence that BDNF, signaling through its receptor TrkB, is involved in epilepsy. However, both proepileptogenic and antiepileptogenic effects have been attributed to BDNF/TrkB signaling. This study characterizes the less well-understood mechanisms by which reductions in BDNF potentiate seizure development by influencing inhibitory transmission.
Potential for seizure control of isovaline in EpilepsyDamian Shin, Ph.D. Assistant Professor Albany Medical College Albany, NY, United States
Epilepsy is a neurological disorder that affects 65 million people worldwide and is characterized by recurrent seizures. While many patients are treatable with anti-epileptic drugs (AEDs), some do not respond and others experience adverse effects. Therefore, there is considerable interest in identifying novel candidates for AED development. Here, I assess whether isovaline, an amino acid with a unique structure that attenuates seizure-like events in brain slices, has utility as a new AED in acutely and chronically seizing animals. If so, then a new class of drugs may revolve around the unique properties of this amino acid.
Ultra High Resolution DTI of the Hippocampus in EpilepsyMichael Zeineh, Ph.D. Assistant Professor Stanford University Stanford, CA, United States
Epilepsy is when patients have frequent seizures. Often, there is a defect in a part of the brain causing these seizures. If the defect can be found, surgery can eliminate the seizures. However, current techniques often cannot find the defect. Diffusion imaging is a new method that looks at the microscopic motion of water in the brain. This project will use high-definition diffusion imaging in epilepsy patients to identify with greater accuracy the parts of the brain that are causing the seizures.